Advair, a combination inhaler, tackles asthma and COPD using two active ingredients: fluticasone propionate and salmeterol. Fluticasone propionate is a corticosteroid; it reduces inflammation in your airways. This directly addresses the underlying cause of airway narrowing in these conditions. Salmeterol, a long-acting beta2-agonist (LABA), relaxes the muscles surrounding your airways, providing quick relief from bronchospasm and improving airflow. The combined action means Advair offers both anti-inflammatory and bronchodilator effects.
Fluticasone propionate works by suppressing the release of inflammatory substances like leukotrienes and histamine. By decreasing inflammation, it prevents further airway narrowing and reduces the frequency of symptoms. This contributes to long-term control of your condition.
Salmeterol, on the other hand, acts quickly by stimulating beta2-receptors in your lungs, leading to smooth muscle relaxation. This rapid bronchodilation provides immediate relief from shortness of breath and wheezing. Its long-acting nature ensures sustained relief for up to 12 hours.
This dual approach – combining inflammation reduction with bronchodilation – is key to Advair’s effectiveness. It helps manage both the underlying inflammation and the immediate symptoms of asthma and COPD, offering a comprehensive approach to airway management. Remember to consult your doctor for personalized advice regarding your treatment.
